Folgen
Viviana Bazan
Viviana Bazan
University of Palermo
Bestätigte E-Mail-Adresse bei usa.net
Titel
Zitiert von
Zitiert von
Jahr
Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’study
HJN Andreyev, AR Norman, D Cunningham, J Oates, BR Dix, ...
British journal of cancer 85 (5), 692-696, 2001
11092001
STAT proteins: from normal control of cellular events to tumorigenesis
V Calò, M Migliavacca, V Bazan, M Macaluso, M Buscemi, N Gebbia, ...
Journal of cellular physiology 197 (2), 157-168, 2003
8472003
The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumor Site, Type of …
A Russo, V Bazan, B Iacopetta, D Kerr, T Soussi, N Gebbia
Journal of clinical oncology 23 (30), 7518-7528, 2005
5522005
Founder mutations in BRCA1 and BRCA2 genes
R Ferla, V Calo, S Cascio, G Rinaldi, G Badalamenti, I Carreca, ...
Annals of Oncology 18, vi93-vi98, 2007
4132007
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype
V Bazan, M Migliavacca, I Zanna, C Tubiolo, N Grassi, MA Latteri, ...
Annals of Oncology 13 (9), 1438-1446, 2002
3102002
miR‐20b modulates VEGF expression by targeting HIF‐1α and STAT3 in MCF‐7 breast cancer cells
S Cascio, A D'Andrea, R Ferla, E Surmacz, E Gulotta, V Amodeo, V Bazan, ...
Journal of cellular physiology 224 (1), 242-249, 2010
2762010
Male breast cancer
L Ottini, D Palli, S Rizzo, M Federico, V Bazan, A Russo
Critical reviews in oncology/hematology 73 (2), 141-155, 2010
2662010
Ras family genes: an interesting link between cell cycle and cancer
M Macaluso, G Russo, C Cinti, V Bazan, N Gebbia, A Russo
Journal of cellular physiology 192 (2), 125-130, 2002
2412002
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
G Badalamenti, D Fanale, L Incorvaia, N Barraco, A Listi, R Maragliano, ...
Cellular immunology 343, 103753, 2019
2362019
Hereditary ovarian cancer
A Russo, V Calò, L Bruno, S Rizzo, V Bazan, G Di Fede
Critical reviews in oncology/hematology 69 (1), 28-44, 2009
2002009
Patterns of genomic instability in gastric cancer: clinical implications and perspectives
L Ottini, M Falchetti, R Lupi, P Rizzolo, V Agnese, G Colucci, V Bazan, ...
Annals of Oncology 17, vii97-vii102, 2006
1962006
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma
G Bronte, S Rizzo, L La Paglia, V Adamo, S Siragusa, C Ficorella, ...
Cancer treatment reviews 36, S21-S29, 2010
1782010
Circular RNA in exosomes
D Fanale, S Taverna, A Russo, V Bazan
Circular RNAs: biogenesis and functions, 109-117, 2018
1752018
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
F Passiglia, G Bronte, V Bazan, C Natoli, S Rizzo, A Galvano, A Listì, ...
Oncotarget 7 (15), 19738, 2016
1742016
Potential role of ANGPTL4 in the cross talk between metabolism and cancer through PPAR signaling pathway
L La Paglia, A Listì, S Caruso, V Amodeo, F Passiglia, V Bazan, D Fanale
PPAR research 2017 (1), 8187235, 2017
1732017
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia …
V Bazan, V Agnese, S Corsale, V Calo, MR Valerio, MA Latteri, S Vieni, ...
Annals of oncology 16, iv50-iv55, 2005
1732005
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study
B Iacopetta, A Russo, V Bazan, G Dardanoni, N Gebbia, T Soussi, D Kerr, ...
Annals of oncology 17 (5), 842-847, 2006
1572006
The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies
LR Corsini, G Bronte, M Terrasi, V Amodeo, D Fanale, E Fiorentino, ...
Expert opinion on therapeutic targets 16 (sup2), S103-S109, 2012
1522012
Breast cancer genome-wide association studies: there is strength in numbers
D Fanale, V Amodeo, LR Corsini, S Rizzo, V Bazan, A Russo
Oncogene 31 (17), 2121-2128, 2012
1502012
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
S Rizzo, G Bronte, D Fanale, L Corsini, N Silvestris, D Santini, G Gulotta, ...
Cancer treatment reviews 36, S56-S61, 2010
1392010
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20